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Abstract—
We introduce a new computer aided detection and diagnosis
system for lung cancer screening with low-dose CT scans that
produces meaningful probability assessments. Our system is
based entirely on 3D convolutional neural networks and achieves
state-of-the-art performance for both lung nodule detection and
malignancy classification tasks on the publicly available LUNA16
and Kaggle Data Science Bowl challenges. While nodule detection
systems are typically designed and optimized on their own, we
find that it is important to consider the coupling between detec-
tion and diagnosis components. Exploiting this coupling allows us
to develop an end-to-end system that has higher and more robust
performance and eliminates the need for a nodule detection false
positive reduction stage. Furthermore, we characterize model
uncertainty in our deep learning systems, a first for lung CT
analysis, and show that we can use this to provide well-calibrated
classification probabilities for both nodule detection and patient
malignancy diagnosis. These calibrated probabilities informed by
model uncertainty can be used for subsequent risk-based decision
making towards diagnostic interventions or disease treatments,
as we demonstrate using a probability-based patient referral
strategy to further improve our results.
I. INTRODUCTION
Lung cancer is both one of the most common cancers and
the leading cause of cancer death, accounting for approxi-
mately a quarter of all cancer related deaths in the US [1].
The high mortality rate associated with lung cancer is in part
because its symptoms become apparent only after the cancer
is already at an advanced stage. Low-dose Computerized To-
mography (CT) has been proposed as a safe and effective tool
for preventative screening of high-risk populations. Annual CT
screening could reduce lung cancer mortality by at least 20%
after 7 years relative to annual chest radiography [2].
While lung CT screening has the potential to dramatically
reduce the number of lung cancer related deaths, the burden on
radiologists to make screening accurate and efficient for large
volumes of CT scans is high. Automated algorithmic solutions
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may help reduce this burden, but interfacing between algo-
rithmic solutions and doctors is also a challenge when these
algorithms cannot reliably communicate their uncertainty. To
address these needs, we introduce an end-to-end probabilistic
diagnostic system for lung cancer built on deep 3D convolu-
tional neural networks (CNNs). Our system directly analyzes
CT scans and provides calibrated probabilistic scores that
accurately characterize uncertainty.
Our system has two main components: 1) a Computer-
Aided Detection (CADe) module that detects and segments
suspicious lung nodules, and 2) a Computer-Aided Diagnosis
(CADx) module that performs both nodule-level assessment
and patient-level malignancy classification by analyzing suspi-
cious lesions from CADe. Both our CADe and CADx modules
achieve comparable to or better performance than the best
published CADe and CADx systems on the LUNA16 [3] and
Kaggle Data Science Bowl 2017 [4] benchmarks, even though
our system is only trained on the limited data and labels
provided by these datasets, in contrast to [5], [6], which utilizes
additional training data.
We further demonstrate that the results from our system
have meaningful probabilistic interpretations because our ap-
proach integrates model uncertainty in all classification eval-
uations. To the best of our knowledge, model uncertainty has
not been considered in the context of lung CT analysis before.
Since model uncertainty allows us to quantify the uncertainty
in model predictions emanating from lack of training data [7],
by quantifying and including model uncertainty, our system
can more reliably assess out-of-cohort data without making
overly-confident predictions, making it more trustworthy for
real-world usage. We show that the incorporation of model un-
certainty makes the outputs of both CADe and CADx systems
well-calibrated to the original data distribution and thus the
probabilities output by our systems are directly interpretable
as real probabilities. Based on these probabilities, we further
propose patient referral strategies for both CADe and CADx.
An important aspect of any CADe/CADx system is the
coupling between different processing and decision making
components and how the performance of each component
affects the overall performance. Malignant nodules may be
missed by a CADe system tuned for high precision, while
excess false positive candidates from a CADe system with high
recall may overburden any CADx system that has not been
developed to be resilient to those types of false positive candi-
dates. The recall-precision trade-off of the CADe systems used
both for generating training and evaluation nodule candidates
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directly impacts the performance of the CADx system. Due to
this inherent coupling, we develop and study both components
together.
The notion of jointly-developed CADe/CADx challenges
common practice in the lung screening industry, where CADe
and CADx are considered as independent products. Much of
the previously published research focuses on optimizing either
CADe alone [8], [9], [10], [11] or CADx alone [12], [13], [14],
[15], [16], [17], without careful consideration of how they
are affected by each other. Patient-level end-to-end diagnosis
using machine learning with diagnosis-confirmed labels has
been largely unaddressed until the release of the Kaggle Data
Science Bowl [4] dataset, which encourages the development
of joint CADe/CADx systems that achieve the best end-to-end
performance.
We for the first time systematically study the CADe/CADx
coupling and show that an individually-optimized CADe sys-
tem (e.g., for the LUNA16 challenge) can be highly sub-
optimal for automated CADx, i.e., cancer diagnosis. While
much effort is typically put into reducing the false positives
from CADe, our CADx component is not only robust to our
maximum CADe false-positive rate (FPR) of approximately 8
candidates per patient (the largest of the proposed LUNA16
evaluation points) but actually performs much better when
trained on this data compared to a cleaner sample. This demon-
strates that CADe approaches optimized for performance on
the LUNA16 CADe benchmark may not perform as well when
used as part of a full CADe/CADx system.
The rest of the paper is organized as follows. In Section
II, we review the relevant literature on deep learning based
CADe/CADx approaches to address lung cancer diagnosis and
briefly compare the most relevant ones to our system. Our
overall system model is explained in Section III. Section IV
describes the datasets we employ to train and evaluate our
models. The details of the developed CADe and CADx models
are provided in Sections V and VI, respectively. We present
our CADe/CADx results and coupling analysis in Section VII
and provide a discussion on calibration and referral strategies
in Section VIII. Finally, concluding remarks are presented in
Section IX.
II. RELATED WORK
While traditional CAD methods have relied on hand-
engineered features and conventional image processing meth-
ods [18], recent advances in deep learning for computer vision
have resulted in a major shift towards deep learning based
solutions [19]. Multiple independent studies have shown that
deep learning outperforms traditional approaches in lung CT
analysis and results in more robust solutions, thanks to its
ability to automatically learn useful feature representations
from data [12], [20]. Therefore, while the literature on lung
CT analysis is vast, we focus only on related work based on
deep learning in this section.
Although earlier deep learning CADe approaches used 2D
image slices [20], 3D volumetric images provide more infor-
mative features leading to improved performance [8], [9], [10],
[21], [22], [11]. The majority of proposed CADe approaches
consist of two steps [8], [9], [10], [11]: 1) a nodule candidate
extraction step that uses a segmentation network, e.g., [23], or
a region proposal network, e.g., [24]; and 2) a false positive
reduction step that uses a 3D CNN model for nodule-level
detection. Most recently, the authors in [22] proposed a single-
step CADe model that is based on a 3D dense CNN to
perform nodule detection in one step. Their model achieved a
LUNA16 score of 0.897, outperforming previously proposed
CADe models. In contrast, our combined CADe/CADx system
does not require a second false positive reduction step since
our CADx model is relatively insensitive to false positives.
However, we did train a CADe scoring network in order
to produce a comparable LUNA16 benchmark score and
achieved a LUNA16 score of 0.921, which, to the best of
our knowledge, is the best published result on this dataset.
The majority of deep learning based lung CADx approaches
use the LIDC-IDRI [25] dataset, which is labeled with nodule
annotations and malignancy risk scores from four different
radiologists [12], [13], [14], [15], [16], [17], [21]. Although
this dataset is useful for developing nodule detection and
nodule-level malignancy prediction models, the associated ma-
lignancy labels represent subjective opinions of the annotator
radiologists, which have not been confirmed by pathology
diagnosis. There is also significant inter-observer variability
among radiologists [14], which complicates the verification of
obtained CADx results. Further, the vast majority of published
research work addresses either CADe or CADx alone, whereas
in real life the performance of the overall CADx system
is directly impacted by the performance of the preceding
CADe model. In addition to the LIDC-IDRI dataset, which has
nodule-level annotations, a second dataset that was released
by the National Cancer Institute for the 2017 Data Science
Bowl on Kaggle has patient-level binary malignancy labels.
The Kaggle dataset does not have nodule-level annotations,
but its patient-level labels have been confirmed by pathology
diagnosis. This is more representative of a real world test
scenario where a CAD system gets access to raw CT scans
and has to provide end-to-end malignancy decisions based only
on those scans without relying on external nodule annotation
information.
There are two research papers that propose an end-to-end
CADe/CADx system and use the Kaggle dataset similar to
ours [5], [6]. The first one, [5], uses a 3D region-based
convolutional neural network (R-CNN) for nodule detection
followed by multiple instance learning using a leaky noisy-
OR combination approach for malignancy classification. The
authors of [5] examined each CT scan in the Kaggle training
data and hand-annotated suspicious nodules to curate new
training data. They then used those annotations along with the
LIDC-IDRI dataset to train their nodule detection, i.e., CADe,
model. Their final system achieves a CADx performance of
0.87 Area Under the ROC (AUROC) curve on the Kaggle
test set, which, to the best of our knowledge, is the best
published CADx performance. In contrast, our models were
not trained with any additional annotations besides what have
been provided by the LIDC-IDRI and Kaggle datasets, and
still achieve an equally good CADx performance. The second
CADe/CADx paper that uses the Kaggle dataset [6] uses
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Fig. 1. Our overall CAD system diagram. Since CADx performance is so
reliant on the quality of the nodule candidates generated by the CADe, both
were developed simultaneously to achieve the best overall performance.
models trained on the NLST dataset [2], which is a superset
of the Kaggle dataset and includes almost twice as much
training data as the Kaggle training data, and achieves a CADx
performance of 0.84 AUROC on the Kaggle test set.
III. CAD SYSTEM MODEL
Here we introduce our CADe/CADx system and provide an
overview of the key components. The details pertinent to each
individual component are provided in Sections V and VI. The
overall system diagram is shown in Figure 1. Our system takes
a raw 3D CT scan of the lung as input and provides as outputs
a per-patient malignancy classification probability, per-nodule
malignancy scores, and segmented lung nodule candidates.
The system can refer patients or nodules whose results have
a high degree of uncertainty to a radiologist for confirmation.
As a first step, we preprocess each full 3D scan to a
consistent format, described in further detail in Section IV.
The preprocessed 3D scan is then fed into the CADe module,
which performs 3D segmentation. The goal of our CADe
module is to identify and localize lung nodules with the
highest possible recall. The output of CADe module is a list
of identified lung nodules which are then fed into our CADx
module. CADx module uses two cascaded 3D deep learning
models. The first model ranks the candidates based on their
malignancy risk. The second model then uses that ranking
to select the top-k candidates and perform multiple-instance
classification to make a patient diagnosis.
The full system is developed and tuned simultaneously,
since CADx performance is dependent on CADe performance.
This is different than current state-of-the-practice where CADe
and CADx components are treated as independent components
and optimized separately. As we show quantitatively in Section
VII, CADe approaches optimized for performance on the
LUNA16 benchmark may not perform as well when used as
part of a full CADe/CADx system. In particular, when the
CADx system is trained with candidates with a high FPR,
it becomes much more robust to false positive candidates,
resulting in improved performance regardless of the underlying
CADe system’s FPR (see Section VII-C.)
IV. DATA
A. Lung CT Datasets
Our lung cancer system is based on two publicly-available
low-dose CT scan datasets. The first is the LIDC-IDRI [25]
dataset, which contains lesion annotations from four experi-
enced thoracic radiologists. This dataset is used for both our
CADe and CADx components. We use the curated version
of this dataset provided as part of the LUNA16 challenge
[3], which includes 888 patients and consensus labels based
on the agreement of 3/4 radiologist annotators, resulting in
a total of 1186 annotated nodules. We further associate the
malignancy scores given by each of the annotating radiologists
to these consensus nodule labels. Unfortunately, the LIDC-
IDRI annotations do not include very large nodules or masses,
which are important for full patient diagnosis. This is an
important limitation of this dataset for use in a standalone
CADe system.
The second dataset we use is the one provided by the
National Cancer Institute for the 2017 Data Science Bowl on
Kaggle [4]. It has two separate sets of CT scans, namely Stage-
1 and Stage-2, which were used as training and test sets for the
Kaggle challenge. Stage-1 data consists of 1595 patients, out
of whom 419 (∼26%) were diagnosed with lung cancer within
one year after the CT scans were acquired. Stage-2 includes
506 patients, out of whom 153 (∼30%) were diagnosed with
lung cancer. Stage-2 data is generally more recent and higher
quality (thinner slice thickness) which helps test the ability
of CADx systems to generalize beyond their training data.
Kaggle data was used for the training (Stage-1) and testing
(Stage-2) of the CADx component of our system.
B. Data Preprocessing and Augmentation
Here we provide details on the data preprocessing and
augmentation steps performed prior to CADe/CADx model
training. CT scan preprocessing involved only clipping the
scan image range to between -1000 and 400 Hounsfield units
in order to remove most of the variation due to bone and
resampling the images such that voxels measured 1 mm in
each dimension. Images were normalized to have a mean voxel
value of 0 and variance of 1 before being input to the neural
networks, as is standard.
We used extensive data augmentation (shown in Figure
2) to reduce overfitting and maximize the transfer learning
across images taken with different setups. Data augmentation
was used during training of all of our models, but not
used at test time. Our affine transform augmentation was
made up of uniformly sampled 3D rotations and reflections,
as well as smaller random scaling from N (0, 0.06)% and
translations from N (0, 1) mm, independently in all three
dimensions. Additional image transforms included random
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Fig. 2. Randomly sampled augmentations of a single nodule demonstrating
our extensive augmentation transforms used during model training.
gamma transformations sampled from U(0.7, 1.3), Gaussian
blur or unsharp masking with σ sampled from U(0, 1.5), and
additive Gaussian noise with σ sampled from N (0, 0.03). To
ensure the highest possible CADe recall for large nodules,
additional aggressive scaling augmentation (3× scaling dis-
tribution above, for upsampling) was used in the training of
that component. This allowed our CADe system to find nodule
candidates significantly larger than any actually annotated in
the LIDC-IDRI dataset.
V. CADE
Our CADe system was developed to have as high of a
sensitivity/recall as possible for identifying and localizing
pulmonary nodules while still keeping the number of false
positives low enough to be manageable for our CADx system.
It is able to analyze any size CT scan and uses only local visual
information to make its decisions. Our CADe system is made
up of 1) a 3D segmentation network, which labels every voxel
of the CT scan with a nodule probability, and 2) a 3D scoring
network, which computes refined nodule probability estimates
for full nodule candidates generated from the segmentation
and allows for both greater interpretability and false positive
reduction. The following subsections explain these networks
in detail.
A. Segmentation for Candidate Extraction
Our primary nodule segmentation network is a 3D fully-
convolutional neural network based on the V-Net architecture,
which has been demonstrated to be effective for 3D medical
image segmentation [23]. Our architecture1 uses three encoder-
decoder block pairs, with corresponding skip connections, in
addition to the input and output blocks. Our encoder blocks
are made up of a 2× downsampling convolution, two layers
of kernel size 3 convolutions, and residual connection to
the output. Decoder blocks are the same, but with a 2×
upsampling deconvolution. The innermost encoder-decoder
block pair include channel-wise dropout between the sampling
convolution and the two main convolutional layers. All blocks
use instance normalization [26] instead of batch normalization
as well as ReLU nonlinearities.
For training, we use the LUNA16 pulmonary nodule annota-
tions, which provide nodule centers and diameters, to annotate
1We began with the V-Net architecture as described in the paper [23] and
tuned the number of layers, number of features, non-linearity functions, and
normalization layers based on performance on the LUNA16 dataset.
Fig. 3. Sample nodule segmentations from our CADe segmentation model,
sliced through the center of each nodule candidate. First row: Input CT
scan images from LIDC-IDRI test data. Second row: Our corresponding
segmentation probabilities. Third row: (Spherical) voxelwise labels extracted
from the LUNA16 annotations.
individual voxels of CT scans with spherical masks. Since the
number of voxels corresponding to the nodule annotations is
very small compared to the total number of voxels, and each
CT scan is too large to realistically use to train our network,
we sample 643-shaped blocks from the original images. For
each patient, we sample blocks near known nodules with a
probability of 1− 0.7N and sample randomly from the image
the with a probability of 0.7N , where N is the number of
nodules for that patient. We employed this random sampling
strategy in order to ensure that the network is exposed to true
nodules a sufficient number of times as well as a diverse
selection of background. We train the network with a cross
entropy loss function that weights voxels within a nodule
twice as much as background voxels. Each patient scan is seen
once per epoch, regardless of how many nodules are contained
within. Our network is trained with 16 block samples per batch
using the Adam optimizer [27] with learning rate of 10−3 for
2500 epochs.
As full preprocessed CT scan images are too large to fit
into GPU memory2 while being passed through the trained
nodule segmentation model at test time, we split images into
eight 2563-shaped overlapping blocks and stitch the output
segmentations together, weighting voxels in the overlapping
edge regions by how much of their field-of-view was contained
within the borders of their respective input blocks. This results
in a full image segmentation that is as good as if the entire
image were evaluated by the network in one pass on a CPU,
but requires an order of magnitude less time.
CADe candidates are generated from the full segmented
image by thresholding the output voxel scores, applying a
nearest-neighbors binary opening filter, and labeling all sepa-
rate regions based on a voxel connectivity of one. The center
of each nodule candidate is taken to be the center of mass of
the voxel scores of each constituent voxel after thresholding.
Sample segmentations of generated candidates on LUNA16
test data are shown in Figure 3 alongside the original spherical
annotation.
B. False Positive Reduction for LUNA16 Evaluation
All generated candidates are supplied to the CADx system.
However, for the purposes of evaluating our CADe system on
2We used an NVIDIA Quadro GP100 or equivalent for all model training
and evaluation described in this paper.
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the LUNA16 benchmark, we developed a scoring network that
operates on 323-shaped blocks around the candidate center.
The architecture of this network is shown in Figure 4. The
network was trained with the SGD optimizer (learning rate
0.01, momentum 0.9, and 0.8× learning rate decay every
100 epochs) with batches of 16 candidates for 2500 epochs,
with true nodule candidates weighted twice as heavily as false
positive candidates in the cross-entropy loss. As we show in
Section VII, our scoring network can be used to dramatically
reduce the number of false positives found by the segmentation
network.
Our candidate scoring network outputs include model un-
certainty as quantified by Monte Carlo (MC) dropout [28],
[7]. We show in Section VIII that the addition of this model
uncertainty makes these scores well-calibrated to the LUNA16
data distribution and thus the probabilities output by the
network for each candidate are directly interpretable as real
probabilities of being a nodule.
VI. CADX
Our CADx system classifies each CT scan as malignant or
benign while associating malignancy scores to each individual
candidate (i.e., suspicious lung nodule) that it processes. The
CADx system is composed of two consecutive 3D convo-
lutional neural networks. The first network is a regression
network that we use to rank candidates for each CT scan
based on their malignancy risks. As each CT scan may have a
large number of candidates, the ranking step enables us to
reduce noise and focus on candidates that are more likely
to be malignant. The second network performs classification
by processing the top-k nodule candidates ranked by the first
network using a multiple instance learning approach. We refer
to the first and the second networks as malignancy ranking
and malignancy classification networks, respectively.
A. Malignancy Ranking Network
Our malignancy ranking network architecture has the same
basic structure as the CADe candidate scoring network, de-
scribed in Figure 4. To train our ranking network, we regress a
label derived from the malignancy scores from the LIDC-IDRI
dataset [25] provided by four different radiologists. In these
annotations, each radiologist assigned an integer malignancy
score between 1 and 5 for each significant nodule they were
able to identify (1 and 5 indicating the least and the most
malignant scores, respectively). As a result, each nodule has
between one and four scores. These scores are subjective
in that they were not confirmed by follow-up biopsies nor
were they consistent between different radiologists. Therefore,
they merely provide noisy labels which we use to train
our malignancy ranking network for the purpose of ranking
candidates detected in each CT scan. To reduce noise in the
training data, we selected nodules that were scored by at least
three radiologists and averaged their scores to come up with
final nodule malignancy scores for training. We assigned a
score of 1 for candidates that were either scored by fewer
than three radiologists, were too small to be scored at all, or
were false positive detections.
Base Neural Network Model
Type Filters Output
Conv. Block 32 16×16×16
Conv. Block 64 8×8×8
Conv. Block 128 4×4×4
Fully Connected + PReLU 1024
Dropout 1024
Fully Connected 1
Convolutional Block
Type Size/Stride
Convolutional + PReLU 5×5×5/1
Batch Normalization
Maxpool 2×2×2/2
Fig. 4. Base neural network architecture used for nodule candidate scoring,
malignancy ranking, and multiple-instance malignancy classification. The
architecture hyperparameters were found through experimentation on the two
CADx tasks, namely malignancy ranking and classification.
Eight subsets of the LUNA16 dataset were selected for
training the malignancy ranking and two subsets were selected
for development. During initial training, we randomly select
nodules with at least three radiologist scores for the first 50
epochs. After that, we randomly select those nodules 90% of
the time and sample randomly from the remaining set, which
only has nodules of score 1, 10% of the time. This can be
seen as a curriculum learning strategy to prevent the network
from biasing towards benign nodule scores since most of the
detected candidates are benign. We train the network using
the Adam optimizer [27] with a learning rate of 10−4 with
mean absolute error as the loss function for 750 epochs with
a batch size of 32 candidates. The ranking network training
and hyperparameter tuning was performed using a library of
LUNA16 nodule candidates created by our earlier work on
standalone CADe [29].
The malignancy ranking network generates a list of ranked
candidates for each CT scan based on their malignancy risks.
These ranked candidates are then used to train or be evaluated
by the malignancy classification network.
B. Malignancy Classification Network
Patient-wide malignancy classification is the final step in our
CADe/CADx pipeline. Our malignancy classification network
processes a predefined number of ranked nodule candidates
and outputs a probabilistic malignancy score for each CT scan.
It also assigns a non-probabilistic malignancy risk score for
each candidate that it processes.
We use an attention-based multiple instance learning (MIL)
framework to train our malignancy classification network
[30]. The MIL framework is based on a convolutional neural
network shared by all selected candidates followed by a
combination layer that combines features of each candidate
using an attention mechanism. As our shared network, we use
the same basic architecture described in Figure 4 with the last
fully connected layer removed. The shared network generates
a feature vector hi ∈ R1024×1 for each candidate i. These
feature vectors are then combined via the following attention
model:
xi = tanh(W1hi) (1)
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y = softmax(wT2X) (2)
p = sigmoid(wT3Hy) (3)
where W1 ∈ R128×1024, w2 ∈ R128×1, and w3 ∈ R1024×1
denote the learned weights of the attention-based combination
model; and X = [x1, . . . ,xk] and H = [h1, . . . ,hk] denote
the concatenated feature vectors from the k candidates. Note
that we have omitted the bias terms above to keep the notation
simple, though they exist in the actual implementation.
The attention mechanism allows the model to learn
permutation-invariant weights as a function of the feature
vectors, denoted by y in (2), where yi ∈ [0, 1] and
∑
i yi = 1.
These weights are then used to compute a weighted average
of the feature vectors themselves, which is fed into a fully
connected layer followed by a sigmoid nonlinearity to compute
a probabilistic malignancy score for each patient, as shown in
(3). We explored other combination methods such as Noisy-
OR (NOR) [31], Leaky NOR (L-NOR) [5], and log-sum
exponentiation (LSE) [32]. We found that they did not work as
well as the attention-based model for our dataset and they were
harder to optimize as L-NOR and LSE introduced additional
hyperparameters.
For training the malignancy classification network, we
combined the Kaggle Stage-1 dataset with a subset of the
LUNA16 dataset as our training and development data, and
set aside Kaggle Stage-2 dataset as our test data. Specifically,
we selected the LUNA16 patients having a nodule with at least
three radiologist scores and an average score ≥ 4 as positive
(malignant), and patients having no radiologist annotations or
patients with all their nodules having an average score ≤ 2
as negative (benign). This procedure added 556 patients to
our training data, out of whom 169 (∼30%) were labeled
malignant. As a result, we ended up with a total of 2101
patients (556 from LUNA16 and 1595 from Kaggle Stage-1)
for training.
One limitation of the LUNA16 dataset is that the radiologist
annotators were specifically instructed to ignore nodules that
were larger than 30 mm. As a result, machine learning based
CADe systems trained with the LUNA16 dataset could learn
to ignore large nodules even when aggressive data augmenta-
tion (specifically zooming) techniques are employed during
training. Nodule size, however, is an important indicator
for malignancy, with larger nodules having a much higher
likelihood of being malignant. To alleviate this problem, we
use two sets of candidates from the CADe system. The first
set has candidates from the original isotropically sampled
(1 mm)3/voxel scans. To be able to detect large nodules, we
created a second candidate set by downsampling each scan to
(2 mm)3/voxel and passing them through our trained CADe
system. These candidates are then similarly passed through our
trained malignancy ranking network to create a ranked list of
downsampled candidates.
To train the malignancy classification network, we select the
top-k candidates from each ranked candidate list (the original
and downsampled) where we treat k as a hyperparameter to
optimize. For patients with less than k candidates, we use
the existing number of candidates, which does not affect our
training procedure. We set aside 300 patients for development
Label: Malignant, CADx Prob.: 0.97
0.58 0.42
Label: Malignant, CADx Prob.: 0.94
0.92 0.08
Label: Benign, CADx Prob.: 0.24
0.78 0.11 0.11
Label: Benign, CADx Prob.: 0.03
0.16 0.26 0.29 0.29
Fig. 5. Example nodule candidates with CADx malignancy probabilities
along with corresponding candidate attention weights. Each row represents
candidates from a specific patient. The scores on top of each candidate are
the corresponding CADx network attention weights, which sum up to 1 and
represent how much each candidate contributes relatively to the final CADx
score. Estimated patient-level CADx malignancy probability is given in the
bottom of each row.
and used the remaining set for training. Our network was
trained using the SGD optimizer with momentum 0.9 and an
initial learning rate of 0.01, which was decreased by a factor
of 2 every 50 epochs. We used binary cross entropy as the
loss function and trained the network with a batch size of 32
scans for 750 epochs. Our best performing CADx model (as
shown by Figure 8) uses a total of 4 candidates, i.e., top-2
from each of the original and downsampled candidate lists.
We obtained model uncertainty estimates using a combina-
tion of the MC dropout [7] and the deep ensembles method
[33] by training five different models with different train
and development dataset splits. We show in the next section
that this method provides calibrated malignancy probabilities
which can be interpreted as true probabilities and used as a
reliable risk-utility metric for subsequent decision making in
clinical settings.
For visualization, we show nodule candidates from a few
example patients in Figure 5. The corresponding attention
weights shown on top of each row represent how much each
candidate contributes to the overall malignancy prediction
probability for a given patient. One can interpret these weights
as relative malignancy scores for patients with high estimated
malignancy probabilities.
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VII. RESULTS
We evaluate our CADe system on the LUNA16 benchmark
and our CADx system on the Kaggle Stage-2 test set. Since
CADx directly relies on CADe, the success of the CADx
system acts as additional validation of the CADe system and
its ability to generalize to an independent dataset. Likewise,
the CADx system is trained and validated on the Kaggle Stage-
1 dataset but tested on the Kaggle Stage-2 dataset, which is
more recent and has different image quality.
A. CADe Results
To evaluate our CADe system on the LUNA16 benchmark,
we use 10-fold cross validation with the prescribed splits and
provided lung volume masks. For each test split, another split
was used as a validation set to select both the corresponding
segmentation model and scoring model checkpoints, while the
other eight were used to train both models. Candidate selection
from the segmented test scans using a segmentation threshold
of 0.2 achieved a sensitivity (or recall) of 96.5% with 19.7
average false positives per scan without any false positive
reduction step. This false positive average is dominated by
candidates from a small number of patients with large regions
of uncertain segmentation.
Our CADe scoring network allows a dramatic reduction
in the number of false positives, while keeping the nodule
sensitivity extremely high. Our CADe sensitivity as a function
of false positive rate per scan is shown in Figure 6 and
the results on the LUNA16 metric are shown in Table I.
Our average LUNA16 metric of 0.921 is comparable to or
better than state-of-the-art published results [22], even though
our CADe is not optimized for the high-precision limit. The
breakdown by nodule diameter in Figure 7 shows that our
CADe performance is strongest on pulmonary nodules with
a diameter greater than 5 mm. This is primarily because our
false positives are dominated by small candidates which are
difficult to distinguish from true positive small nodules.
In addition to the results using our primary V-Net based seg-
mentation architecture, we generate comparison results from
our full training and evaluation pipeline using the standard 3D
U-Net architecture [34], with the number of features per block
tuned for validation performance on the LUNA16 dataset. As
seen in Figure 6 and Table I, the CADe and CADx results
using this comparison architecture are similar to our primary
results, indicating that the success of our CADe system is
based more on the sampling and data-augmentation techniques
used in the training pipeline than the architectural details of
the neural network.
B. CADx Results
Our best performing CADx model was trained and eval-
uated with nodule candidates obtained by setting the CADe
segmentation threshold to 0.5, which resulted in approximately
8 false positives per scan on average without any false positive
reduction step. This kept spurious candidates to a reasonable
level while not removing large nodule candidates not annotated
in LUNA16. This corresponds to a CADe segmentation F1
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Fig. 6. The free response operating characteristic (FROC) for our CADe
candidate generation and scoring system on the LUNA16 dataset, with
patient-bootstrapped 95% confidence interval, and the same results with our
comparison model architecture (3D U-Net.)
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Fig. 7. CADe FROC on LUNA16 data, breaking down the sensitivity by
nodule diameter. CADe sensitivity for the smallest group of nodules (between
3 mm and 5 mm diameter) is significantly worse than the sensitivity for
larger nodules (between 5 mm and 30 mm diameter) at lower thresholds that
correspond to reduced false positives.
score (Dice coefficient) for LUNA16 of 0.40, with 0.25
precision and 0.93 recall.
We trained our CADx model with the top-4 ranked candi-
dates per patient as it provided the best performance on our
development set. We evaluated our final CADx system on the
Kaggle Stage-2 data, which was set aside as our test set. As
shown in Figure 8, our CADx system achieved an average
ROC Area Under the Curve (AUC) of 0.87 on this dataset.
This performance is the same as the winning Kaggle solution
[5], but unlike that solution, did not require us to hand-label
the nodules in the Kaggle Stage-1 data nor ensemble different
CADx solutions as was done by other top-10 Kaggle solutions.
C. CADe-CADx Interaction Studies
We further studied the effect of CADe false positive re-
duction by evaluating our CADx system with Kaggle Stage-
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TABLE I
CADE AND CADX RESULTS BY CADE THRESHOLD FALSE POSITIVE RATE
LUNA16 CADe sensitivity Kaggle Stage-2 CADx AUROC
CADe Primary arch. Comparison arch. Evaluated on nodule cands. from
FP / patient (V-Net based) (3D U-Net) Primary arch. Comparison arch.
1/8 0.832 0.839 0.867 0.869
1/4 0.879 0.888 0.868 0.868
1/2 0.920 0.917 0.863 0.863
1 0.942 0.941 0.868 0.863
2 0.951 0.950 0.866 0.858
4 0.959 0.952 0.869 0.858
8 0.964 0.952 0.869 0.859
average 0.921 0.920
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Fig. 8. The receiver operating characteristic (ROC) curve for our CADx
system on the Kaggle Stage-2 test set, trained on both LUNA16 and Kaggle
Stage-1 data, with patient-bootstrapped 95% confidence interval.
TABLE II
CADX RESULTS BY CADE THRESHOLD FOR TRAINING AND TESTING
FP / Trained on
patient 1/8 1 8
Te
st
ed
on 1/8 0.847 0.848 0.867
1 0.815 0.852 0.868
8 0.753 0.833 0.869
2 candidates filtered by our CADe false positive reduction
model at the LUNA16 evaluation points, shown in Table I. We
again found that our CADx system is relatively insensitive to
false positive candidates from the CADe system and that false
positive reduction steps add no value.
Additionally, we explored the CADe-CADx coupling in
candidate generation in both training and testing stages, shown
in Table II. In addition to our original CADx results trained
using Kaggle Stage-1 candidates with a CADe threshold
equivalent of 8 FP per scan, we fully retrained our CADx
system using candidates filtered at the 1 and 1/8 FP per scan
LUNA16 evaluation points. We found that, not only did the
CADx AUROC degrade significantly, but these CADx systems
were much less robust to false positives. These results show
that the presence of false positive candidates actually benefits
CADx training by improving its internal CADe capabilities,
and thus robustness to false positives.
VIII. CALIBRATION & REFERRAL
In order to generate meaningful probability estimates from
both our CADe and CADx components, we include Bayesian-
motivated model uncertainty and verify that the consequent
estimates are well calibrated on test data. Well-calibrated
probability estimates are useful because they give us the ability
to interpret the nodule candidate and overall malignancy scores
as true probabilities and use them for subsequent decision
making.
Model uncertainty captures the effect of uncertainty in the
neural network parameters (weights and biases) and shrinks
as the model is trained on more, representative data. Model
uncertainty is particularly significant in deep learning, where
models often have millions of free parameters. By quantifying
and including model uncertainty, our system can more reliably
assess out-of-cohort data without making overly-confident
predictions, making it more trustworthy for real-world usage.
For the nodule candidate scoring network, we trained 10
models using each of the 10 LUNA16 data subsets as a test
set. Model uncertainty was approximated by using Monte
Carlo (MC) dropout [28], [7]. This technique randomly drops
out features during both training and testing, allowing us to
perform approximate Bayesian inference by sampling over
these features. The probabilities produced by the candidate
scoring networks thus incorporate uncertainty in the model
weights in addition to uncertainty inherent to the data in-
cluding label noise. In Figure 9, this is shown to produce
well-calibrated probability estimates on the LUNA16 test data.
When model uncertainty is not incorporated, by generating
estimates without dropout at test time as is typical, the prob-
ability estimates from the network tend to be overconfident
in their predictions, as can be seen in the figure. We expect
this difference would be even more dramatic for evaluation on
data with significant domain shift (for example, due to unusual
hardware, procedures or patients).
As mentioned in Section VI-B, we used a combination
of the MC dropout [7] and deep ensembles [33] methods
to assess model uncertainty of our malignancy classification
network. The model ensembling method simply involves train-
ing a model multiple times, starting with randomly initial-
ized parameters, and averaging their results. We trained the
malignancy classification network on five different train and
development splits and used the predictions, obtained by MC
dropout, from these models to assess model uncertainty as
well as boost the performance. Since we only had one test set,
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Fig. 9. Probability calibration curves for the Bayesian approximation and non-
Bayesian (standard) variants of the CADe candidate scoring neural networks,
with patient-bootstrapped 95% confidence intervals. The estimated nodule
probabilities output by the CADe scoring network are well-calibrated when
model uncertainty is included.
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Fig. 10. Probability calibration curves for the Bayesian ensemble and the best
non-Bayesian CADx model, with patient-bootstrapped 95% confidence inter-
vals. The estimated malignancy probabilities output by the CADx Bayesian
ensemble are well-calibrated when model uncertainty is included.
it was more effective to estimate model uncertainty using the
ensemble method combined with MC dropout, which has been
shown in some cases to produce more reliable uncertainties
than the MC dropout alone [33]. The calibration curves are
shown in Figure 10. While the best individual network did not
systematically overestimate uncertainties like was seen for the
CADe candidate scoring network, the ensemble probabilities
appear to be more stably calibrated over the full range of
probabilities.
We explored the potential of using these well-calibrated
probabilities to improve the reliability of our CAD systems
through referral strategies, in which a radiologist could check
the most critical subset of patients and nodules. We found that
referral based on highest entropy,
H(p) = −p ln(p)− (1− p) ln(1− p), (4)
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Fig. 11. The CADe scoring area under the precision-recall curve as a function
of referral percentage, for the entropy referral strategy and a random strategy
(with 95% confidence interval).
was advantageous, particularly for CADe nodule referral. In
Figure 11, the area under the precision-recall curve for our
nodule candidate CADe scoring is plotted as a function of the
percentage of nodules ignored based on this referral strategy.
There is a dramatic improvement in performance, even at a
referral rate below 10%, and the performance on remaining
nodules monotonically approaches 1 as the referral rate is
increased. This further demonstrates that the nodule candidate
scoring probabilities are well calibrated even extremely close
to 0 and 1. The nodule candidate scoring system combined
with a “perfect” radiologist able to evaluate a subset of
candidates could nearly completely eliminate false positive
nodules from the CADe candidate generation process without
missing additional true positive nodules.
Figure 12 shows the effect of our referral strategy on the
malignancy classification results, where we plot the ROC AUC
on the remaining data after referral against different rates of
patient referral. We are able to boost the performance on the
remaining data and get a maximum AUC of 0.885, which
shows that model uncertainty combined with data uncertainty
provide a useful measure to detect patients for which the
network is more likely to make an incorrect classification
decision. However, the decrease in AUC at higher referral
rates indicates that there are incorrect decisions made even
when CADx system is very confident. As illustrated by the
histogram of CADx malignancy scores in Figure 13, this is
a result of patients for whom the CADe system was unable
to find a visibly malignant nodule, either because one does
not exist, it is too large to be detected by CADe trained on
LUNA16 data, or it is simply missed. This is an unavoidable
weakness in probability estimations from systems that rely on
other systems that are imperfect.
IX. CONCLUSIONS
In this paper, we introduced a full CADe/CADx system to
detect and diagnose lung cancer using low-dose CT scans. Our
system uses a cascade of 3D CNNs and achieves state-of-the-
art performance on both lung nodule detection and malignancy
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Fig. 12. The CADx area under the ROC curve as a function of referral
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confidence interval. Note that the confidence interval is wider than the CADe
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Fig. 13. Histogram of CADx malignancy probability estimates for benign
and malignant patients. Note that the mode around 0 for malignant patients is
the reason behind false negatives due to missed nodules by the CADe model.
classification problems on the publicly available LUNA16 and
Kaggle datasets. Moreover, we characterized model uncer-
tainty using Monte Carlo dropout and deep ensembles, and
showed that quantification of model uncertainty enables our
system to provide calibrated classification probabilities, which
makes it reliable for subsequent utility/risk-based decision
making towards diagnostic interventions or disease treatments.
We demonstrated that we can further improve the performance
by using these calibrated probabilities to make patient referral
decisions.
Our CADe/CADx system studies demonstrate that CADe
and CADx modules should be developed and studied jointly if
the goal is to use them as an end-to-end automated diagnostic
tool to diagnose lung cancer. This is in contrast to the
current design paradigm where CADe and CADx modules are
optimized independently for different metrics. We believe that
the importance of joint development in radiology is applicable
to other systems, where the outputs from radiologists, doctors,
and machine learning models are combined to make diagnostic
decisions. For example, a machine learning model maximizing
the performance on a subset of the dataset that is hard
for humans to analyze would be more useful than a model
providing the best performance across the whole dataset.
Although our system demonstrates that 3D CNN models can
be effectively used to analyze lung CT scans, the performance
is still bounded by the limitations of the datasets used to
train our models, such as the lack of large nodule annotations
in the LUNA16 dataset. We tried to alleviate these prob-
lems through intense data augmentation and downsampling,
but these solutions are imperfect. An ideal way to train a
CADe/CADx would be to have datasets that cover a wider
range of nodule sizes and varieties, patients, and scanning
equipment. If a malignant lesion is missed by the CADe
model, the subsequent CADx model has no way of classifying
that scan as malignant, resulting in the biggest source of false
negatives in our system. We believe that further investments in
curating more inclusive datasets will enable the development
of even stronger CADe/CADx models.
As potential future work, we would like to incorporate
patient referral (or reject option) as part the training strategy
and learn models that would automatically reject the most
uncertain decisions. We would also like to visually analyze
learned feature representations to assess whether they could
be used as informative biomarkers and help radiologists better
understand and interpret CADe/CADx results.
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